AlmegaPL CV Health Open Label Study

Completed · Phase 4

Conditions studied: Cholesterol, Triglycerides, Omega-3, Eicosapentaenoic Acid

In brief

The aim of this study is to assess the effectiveness of Almega PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA), on improving blood markers associated with heart health of iwi customers.

Key facts

Study ID

NCT05267301

Run by

Qualitas Health

People needed

250

Starts

2022-05-11

Expected to finish

2022-12-01

Last updated by the study team

2024-02-14

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• New iwi/AlmegaPL subscribers.

You may not qualify if…

• Participants that are already taking AlmegaPL.
• Participants with serious conditions including but not limited to kidney, neurological, immunological, liver and gastrointestinal disease, any heart condition or diabetes).
• Any participant attempting conception, pregnant or breastfeeding

Where it is running

• Arizona State University — Tempe, Arizona, United States
• Qualitas Health — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.